Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This is a randomized single-institution, phase II, open-label clinical trial of neoadjuvant
pembrolizumab with or without low-dose stereotactic radiation therapy (SRT) in stage I-IIIA
non-small lung cancer (NSCLC) patients who are planned to undergo surgical resection of their
lung cancer.